Federal Register of Legislation - Australian Government

Primary content

PB 35 of 2019 Determinations/Health as made
This instrument amends the National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010) to decrease the determined and claimed price of five brands of five pharmaceutical items which took legal effect on 1 April 2019 due to price disclosure.
Administered by: Health
Registered 30 Apr 2019
Tabling HistoryDate
Tabled HR02-Jul-2019
Tabled Senate02-Jul-2019
Date of repeal 17 Sep 2019
Repealed by Division 1 of Part 3 of Chapter 3 of the Legislation Act 2003

PB 35 of 2019

 

National Health (Price and Special Patient Contribution) Amendment Determination 2019 (No. 4)

 

National Health Act 1953

___________________________________________________________________________

 

I, SEAN LANE, Acting Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Determination under section 85B of the National Health Act 1953.

 

Dated           29 April 2019

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SEAN LANE

Acting Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

 


_________________________________________________________________________

1          Name of Instrument

(1)          This Instrument is the National Health (Price and Special Patient Contribution) Amendment Determination 2019 (No. 4).

(2)          This Instrument may also be cited as PB 35 of 2019.

2          Commencement

This Instrument commences on 1 May 2019.

3          Amendment of National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010)

Schedule 1 amends the National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010).

 


Schedule 1     Amendments

 

[1]   Schedule 1, entry for Olmesartan in the form Tablet containing olmesartan medoxomil 20 mg

(a)    omit from the column headed “Determined Price”:                       5.63        substitute:             4.34

(b)   omit from the column headed “Claimed Price”:                              8.88        substitute:             6.85

[2]   Schedule 1, entry for Olmesartan in the form Tablet containing olmesartan medoxomil 40 mg

(a)   omit from the column headed “Determined Price”:                        11.94     substitute:             9.21

(b)   omit from the column headed “Claimed Price”:                              15.20     substitute:             11.73

[3]   Schedule 1, entry for Olmesartan with hydrochlorothiazide in the form Tablet containing olmesartan medoxomil 20 mg with hydrochlorothiazide 12.5 mg

(a)   omit from the column headed “Determined Price”:                        7.07        substitute:             5.75

(b)   omit from the column headed “Claimed Price”:                              8.93        substitute:             7.26

[4]   Schedule 1, entry for Olmesartan with hydrochlorothiazide in the form Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 12.5 mg

(a)   omit from the column headed “Determined Price”:                        13.38     substitute:             10.65

(b)   omit from the column headed “Claimed Price”:                              15.24     substitute:             12.13

[5]   Schedule 1, entry for Olmesartan with hydrochlorothiazide in the form Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 25 mg

(a)   omit from the column headed “Determined Price”:                        14.81     substitute:             12.04

(b)   omit from the column headed “Claimed Price”:                              16.67     substitute:             13.55